سعر سوميناليتا 40 مجم/مل 10 أمبولات عضل 2025

Sominaletta phenobarbitone 40 mg/ml injection, 10 ampoules for intramuscular use, by Alexandria Company for Pharmaceuticals; barbiturate antiepileptic.

• Management of all forms of epilepsy, except absence seizures.Egyptian Drug Authority (EDA), Central Administration of Pharmaceutical Care

• Very common (mainly reported in neonates): hypotension, feeding disorder, sedation and respiratory depression; common: bradycardia and hyponatraemia.General active-ingredient information · Egyptian Drug Authority (EDA), Central Administration of Pharmaceutical Care

• Known hypersensitivity to phenobarbital, other barbiturates or other ingredients; acute intermittent porphyria; severe respiratory depression; severe impairment of renal and hepatic function.General active-ingredient information · Egyptian Drug Authority (EDA), Central Administration of Pharmaceutical Care

• Monitor for suicidal ideation and behaviour.General active-ingredient information · Egyptian Drug Authority (EDA), Central Administration of Pharmaceutical Care
• Serious and sometimes fatal skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported; stop immediately and do not restart.General active-ingredient information · Egyptian Drug Authority (EDA), Central Administration of Pharmaceutical Care
• Avoid sudden withdrawal: severe withdrawal syndrome and rebound seizures may occur; dependence may develop with prolonged use, particularly with a history of drug or alcohol abuse.General active-ingredient information · Egyptian Drug Authority (EDA), Central Administration of Pharmaceutical Care

• Hormonal contraceptivesPhenobarbital increases clearance of estrogens and progestogens; contraceptive failure possible (formulary: consider therapy modification).Egyptian Drug Authority (EDA), Central Administration of Pharmaceutical Care
• Vitamin K antagonists (e.g. warfarin)Listed by the formulary as an interaction requiring therapy modification.Egyptian Drug Authority (EDA), Central Administration of Pharmaceutical Care
• Folic acidFolic acid supplements may lower serum phenobarbital levels and reduce seizure control in some patients.Egyptian Drug Authority (EDA), Central Administration of Pharmaceutical Care

• Avoid during pregnancy unless the potential benefit outweighs the risks; phenobarbital is associated with major and minor congenital defects, and highly effective contraception must be used during treatment.General active-ingredient information · Egyptian Drug Authority (EDA), Central Administration of Pharmaceutical Care
• Breastfeeding is not recommended because of possible sedation of the infant.General active-ingredient information · Egyptian Drug Authority (EDA), Central Administration of Pharmaceutical Care

• Phenobarbital: Acts mainly at the GABA-A receptor chloride-channel complex, enhancing inhibitory neurotransmission (directory pharmacology note).